439RA13029.6%(130/439)RA30.8%(65/211)RA28.5%(65/228)RA(=0.816)(=0.624)( 0.001) 37.0%33.1%(=0.482) 1(=0.237)( Chelidonin 0.001)VAS( 0.001) 1 RA Assessment of clinical features of RA individuals with cervical Chelidonin backbone none of them and instability cervical backbone instability 0.001)RFAKAANAESRWBCPLT RA 16(=0.096)cDMARDs 3(=0.876)bDMARDs(=0.420) 3.? RARA[8]RA[2, 8-10]RA[11] [12]RA[13]RA[12]RARA RARARA29.6%Nguyen[14]1890RA35.6%Neva[15]2006RA44%Yurube[16]2014RA38.6%Blom[17]201316%RAAhn[18]2011RA28.6%2016[11]RA13.2% RA[11]; Chelidonin CTMR[9][5]; RARAAAS[9] RA439RA RAAASVSSAS[2, 7-8, 11, 19]130RARA[20]RAAASSASSAS2%~6%[21]RASASAASVS[22]RASAS2.2% RA[8, 23]RA RA[8, Chelidonin 11, 16-19, 24][25]( Chelidonin 0.001)[8, 11, 16-19, Rabbit Polyclonal to BTLA 24][11][15]RARA RA[26][11, 18-19]RA [11, 18-19, 27]DAS28ESRCRPVAS( 0.001)HGB( em P /em =0.021) CCPRACCP[28]CCP(32.8%)CCP(13.8%)CCPCCPRA cDAMRDsbDAMRDsRA[11, 16, 19, 29] RARA29.6%AASRARAVASCCPHGBRA. .